[Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process].
Сhervyakova. N A NA; Linkova. N S NS; Chalisova. N I NI; Koncevaya. E A EA; Trofimova. S V SV; Khavinson. V Kh VK
Key Findings
- Vilon reduces apoptosis in spleen cells and activates helper T‑cells during ageing
- R‑1 peptide promotes proliferation and differentiation of spleen cells
- Timogen decreases apoptosis and increases proliferation of B‑cells; Crystagen activates B‑cells without promoting new cell growth
Practical Outcomes
- Vilon may be worth watching as a potential immune‑support supplement for aging, but there’s no clear dosing or safety data for people yet. Until human trials are done, it’s best treated as a research lead rather than a concrete protocol.
Summary
The study shows that the peptide Vilon can help keep the spleen’s immune cells healthier as we age by lowering cell death and boosting helper T‑cells, while other short peptides have related but different effects on B‑cells and cell growth. However, the research is basic and doesn’t give dosage or human‑specific guidance, so it’s more a hint than a ready‑to‑use protocol for biohackers.
Abstract
Vilon, Timogen, Crystagen and R-1 short peptides possess various immunoprotective effects in spleen during its ageing. Both R-1 and Vilon peptides activate T-helpers. The effect of Vilon is provided by decreased level of apoptosis, as well as the effect of R-1 peptide is provided by increased proliferation and differentiation processes. Timogen activates B-cells by decreasing apoptosis level and increasing the proliferation of spleen cells. Crystagen also activates B-cells of the immune system; however, the peptide doesn't cause cell renewal in spleen as it ages.
Study Information
pubmed
2014